Jan 12, 2021 5:00 pm EST Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update
Nov 12, 2020 8:00 am EST Immunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020
Sep 04, 2020 4:01 pm EDT Immunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aug 25, 2020 7:30 am EDT Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis
Jun 29, 2020 7:30 am EDT Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis
May 14, 2020 7:30 am EDT Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement